Medical device company dorsaVi Limited
(ASX:DVL) has gained clearance from the US Food and Drug Administration for its ViMove wearable sensors.
The wireless device is placed on the body to measure movement and muscle activity and assesses patients through a series of in-clinic exercises or through everyday activities. ViMove then provides immediate biofeedback and a concise report for the healthcare practitioner.
It’s an important step for dorsaVi, opening up the US market of over 280,000 physical therapists and 660,000 physicians to its products.
DorsaVi plans to add to its sales team to meet international demand. The FDA clearance follows approval for the ViMove device to be sold in New Zealand and the adoption of wearable ViPerform technology by the Sunderland Football Club in the UK.
DorsaVi reported a net loss of $1.07 million dollars for the full year ended 31 December, 2013
